
    
      Eligibility criteria: Gastrointestinal disease or clinical symptoms related to colorectal
      cancer risk submitted to endoscopy. Exclusion criteria consisted of age younger than 18
      years, history of psychiatric illness, and preoperative radiotherapy.

      Outcome: investigated the possible role of the native fluorescence of blood plasma in the
      management of colorectal cancer (CRC) and its feasibility as a new tumor marker. Sample of
      blood was collected from asymptomatic blood donors and from CRC patients. The native
      fluorescence of blood plasma was measured using a conventional spectrofluorimeter.
    
  